Romania Pharmaceuticals & Healthcare Report Q4 2014 - New Study Released

Sales data ha ve provided support to our earlier view that Romania's pharmaceutical market recovery would be consumer - driven. The underlying dynamics have been driven by improvements in the consumer outlook and the country's macroeconomic prospects, in line with the views of our Country Risk team. Provided unemployment continues to pare down and economic growth continues, the pharmaceutical market will continue on its current growth trajectory.

Headline Expenditure Projections

* Pharmaceuticals: RON13.96bn (USD4.17bn) in 2013 to RON14.65bn (USD4.38bn) in 2014; +5.0% in local currency terms and 5.0% in US dollar terms. US dollar forecast revised up from Q314 due to leu appreciation.
* Healthcare: RON30.05bn (USD8.97bn) in 2013 to RON31.30bn (USD9.35bn) in 2014; +4.1% in local currency terms and 4.2% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/879001_romania_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=301

Risk/Reward Rating

Romania has a RRR score of 55.1 out of 100, making it the seventh most attractive pharmaceutical market in the Central and Eastern Europe region. Although over the long term Romania promises a positive growth story, punitive taxes, pricing controls and a lack of funding by the state for reimbursing patients will moderate the market's attractiveness to drugmakers in the short term.

Key Trends And Developments

* The Ministry of Health is proposing an increase in healthcare insurance contributions from 10% of income to almost 15% to address sustainability concerns and bolster funding.
* Domestic drugmakers are ramping up for a pick-up in exports over the coming quarters.
* New criteria will be written up for the reimbursement list, enabling a significant update of included drugs.
* The Ministry of Health withdrew two draft amendments that would have increased the reimbursement budget and enabled favourable pricing structures for drugmakers, drawing criticism from the local drugmakers' association.
* Sanofi transferred the packaging and production operations of 22 of its branded products to Romania, highlight the...

The Romania Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Romania Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Romanian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Romania to test other views - a key input for successful budgeting and strategic business planning in the Romanian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Argentina Pharmaceuticals & Healthcare Report Q4 2014
- Peru Pharmaceuticals & Healthcare Report Q4 2014